Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference

Core Insights - Aileron Therapeutics, Inc. is a biopharmaceutical company focused on developing first-in-class medicines for orphan pulmonary and fibrosis indications [2] - The company will present at the Canaccord Genuity 44th Annual Growth Conference on August 13, 2024 [1] Company Overview - Aileron Therapeutics is advancing a novel pipeline of medicines targeting significant unmet medical needs in orphan pulmonary and fibrosis indications [2] - The lead product candidate, LTI-03, is a synthetic peptide aimed at enhancing alveolar epithelial cell survival and inhibiting profibrotic signaling, currently in Phase 1b clinical trials for idiopathic pulmonary fibrosis [2] - The second product candidate, LTI-01, has completed Phase 1b and Phase 2a clinical trials for loculated pleural effusions and has received Orphan Drug Designation in the US and EU, as well as Fast Track Designation in the US [2]